Ertugliflozin and hospitalization for heart failure across the spectrum of pre-trial ejection fraction: post-hoc analyses of the VERTIS CV trial

Authors

Ambarish Pandey, UT Southwestern Medical School
Ahmed A. Kolkailah, UT Southwestern Medical School
Francesco Cosentino, Karolinska Universitetssjukhuset
Christopher P. Cannon, Harvard Medical School
Robert C. Frederich, Pfizer Inc.
David Z.I. Cherney, University Health Network University of Toronto
Samuel Dagogo-Jack, University of Tennessee Health Science Center
Richard E. Pratley, AdventHealth Translational Research Institute
Nilo B. Cater, Pfizer Inc.
Ira Gantz, Merck & Co., Inc.
James P. Mancuso, Pfizer Inc.
Darren K. McGuire, UT Southwestern Medical School

Document Type

Article

Publication Date

12-21-2023

Publication Title

European Heart Journal

Volume

44

Issue

48

Funding Sponsor

Pfizer

Recommended Citation

Pandey, Ambarish; Kolkailah, Ahmed A.; Cosentino, Francesco; Cannon, Christopher P.; Frederich, Robert C.; Cherney, David Z.I.; Dagogo-Jack, Samuel; Pratley, Richard E.; Cater, Nilo B.; Gantz, Ira; Mancuso, James P.; and McGuire, Darren K., "Ertugliflozin and hospitalization for heart failure across the spectrum of pre-trial ejection fraction: post-hoc analyses of the VERTIS CV trial" (2023). Faculty Publications. 2. 10.1093/eurheartj/ehad639
https://dc.uthsc.edu/fac_pubs/2